LoginSignup
Regeneron Pharms logo

Regeneron Pharms

Stock
Stock
ISIN: US75886F1075
Ticker: REGN
US75886F1075
REGN

Price

Price

CHART BY

Frequently asked questions

What is Regeneron Pharms's market capitalization?

The market capitalization of Regeneron Pharms is $77.13B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is Regeneron Pharms's Price-to-Earnings (P/E) ratio?

The Price-to-Earnings (P/E) ratio (TTM) for Regeneron Pharms is 17.37. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.

What is the Earnings Per Share (EPS) for Regeneron Pharms?

Regeneron Pharms's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $40.41. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Regeneron Pharms's stock?

Currently, 28 analysts cover Regeneron Pharms's stock, with a consensus target price of $1,074.73. Analyst ratings provide insights into the stock's expected performance.

What is Regeneron Pharms's revenue over the trailing twelve months?

Over the trailing twelve months, Regeneron Pharms reported a revenue of $13.85B.

What is the EBITDA for Regeneron Pharms?

Regeneron Pharms's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $4.61B. EBITDA measures the company's overall financial performance.

What is the free cash flow of Regeneron Pharms?

Regeneron Pharms has a free cash flow of $3.44B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

How many employees does Regeneron Pharms have, and what sector and industry does it belong to?

Regeneron Pharms employs approximately 13,450 people. It operates in the Health Care sector, specifically within the Pharmaceuticals: Major industry.

What is the free float of Regeneron Pharms's shares?

The free float of Regeneron Pharms is 105.92M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$77.13B
EPS (TTM) 
$40.41
Free Float 
105.92M
P/E ratio (TTM) 
17.37
Revenue (TTM) 
$13.85B
EBITDA (TTM) 
$4.61B
Free Cashflow (TTM) 
$3.44B

Pricing

1D span
$702.12$716.39
52W span
$693.64$1,210.97

Analyst Ratings

The price target is $1,074.73 and the stock is covered by 28 analysts.

Buy

19

Hold

8

Sell

1

Information

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Employees
13,450
Industries
Pharmaceuticals: Major
Sector
Health Care

Identifier

ISIN
US75886F1075
Primary Ticker
REGN

Knockouts

Join the conversation
Sign upLogin